Esperion Therapeutics (ESPR) Set to Announce Earnings on Tuesday

Esperion Therapeutics (NASDAQ:ESPR) will post its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect Esperion Therapeutics to post earnings of ($0.17) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03. The business had revenue of $32.25 million for the quarter, compared to analysts’ expectations of $26.84 million. During the same period in the previous year, the company earned ($0.76) EPS. On average, analysts expect Esperion Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Esperion Therapeutics Stock Up 1.0 %

Esperion Therapeutics stock opened at $2.08 on Friday. Esperion Therapeutics has a 52-week low of $0.70 and a 52-week high of $3.40. The firm has a market capitalization of $393.95 million, a price-to-earnings ratio of -0.98 and a beta of 0.89. The company has a fifty day simple moving average of $2.34 and a 200-day simple moving average of $2.04.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ESPR. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a report on Monday, March 25th. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Esperion Therapeutics in a report on Wednesday, April 10th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $9.33.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.